TUFTS MEDICAL CENTER INC.

An international research team has developed and validated the first individualized risk prediction model for early-stage classic Hodgkin's lymphoma, called the Early-stage Hodgkin International Prognostication Index (E-HIPI).

OKYO Pharma's Phase 2 trial for urcosimod, a potential first-in-class treatment for neuropathic corneal pain, closed early after treating 17 patients instead of the planned 48, with top-line results now expected in Q3 2025.

CereVasc's eShunt System received its second FDA Breakthrough Device Designation for treating communicating hydrocephalus in pediatric patients aged 12 and older, enabling priority review and enhanced regulatory communication.

• CereVasc has initiated the STRIDE pivotal trial at VCU Health, comparing their novel eShunt System to traditional VP shunts for normal pressure hydrocephalus treatment. • The eShunt System represents the first new treatment option for NPH in over 60 years, offering a minimally invasive endovascular approach to address this condition affecting 800,000 Americans. • The trial aims to demonstrate improved recovery times and reduced complications compared to standard VP shunts, potentially making treatment accessible to more patients with comorbidities.

OKYO Pharma expects to complete enrollment of 48 patients in its Phase 2a trial of OK-101, the first FDA-cleared investigational drug specifically for neuropathic corneal pain, by Q2 2025.

Research from Tufts Medical Center reveals 15% of health plans have inconsistent coverage requirements between medical and pharmacy benefits for the same specialty drugs, creating patient access challenges.

A comprehensive analysis of Google search trends shows adalimumab dominates public interest in psoriasis treatments, with users primarily seeking information about technical details and costs.